Van Berckelaer C, et al. - Researchers analyzed data from 143 patients with inflammatory breast cancer (IBC) who initiated treatment between June 1996 and December 2016, to study the clinical evolution, stromal tumor-infiltrating lymphocytes (sTIL) infiltration, and programmed death-ligand 1 (PD-L1) expression in this patient population. They focused on clinicopathological variables and PD-L1 expression. Two pathologists scored sTIL on standard H&E stained sections. They also confirmed the findings in a validation cohort that consisted of 64 patients with IBC. Findings revealed poor survival in IBC patients. High PD-L1 immunoreactivity on sTIL was detected in IBC. Overall, PD1/PD-L1 inhibitors could have a role as a treatment option for IBC. Response to neo-adjuvant therapy was predicted by PD-L1 expression and sTIL displayed prognostic importance in IBC.